Supplementary Table 2 from Circulating Folate, Vitamin B12, Homocysteine, Vitamin B12 Transport Proteins, and Risk of Prostate Cancer: a Case-Control Study, Systematic Review, and Meta-analysis

Collin, Simon M.; Metcalfe, Chris; Refsum, Helga; Lewis, Sarah J.; Zuccolo, Luisa; Smith, George Davey; Chen, Lina; Harris, Ross; Davis, Michael; Marsden, Gemma; Johnston, Carole; Lane, J. Athene; Ebbing, Marta; Bønaa, Kaare Harald; Nygård, Ottar; Ueland, Per Magne; Grau, Maria V.; Baron, John A.; Donovan, Jenny L.; Neal, David E.; Hamdy, Freddie C.; Smith, A. David; Martin, Richard M.

doi:10.1158/1055-9965.22435444.v1

Supplementary Table 2 from Circulating Folate, Vitamin B₁₂, Homocysteine, Vitamin B₁₂ Transport Proteins, and Risk of Prostate Cancer: a Case-Control Study, Systematic Review, and Meta-analysis

journal contribution

posted on 2023-03-31, 13:22 authored by Simon M. Collin, Chris Metcalfe, Helga Refsum, Sarah J. Lewis, Luisa Zuccolo, George Davey Smith, Lina Chen, Ross Harris, Michael Davis, Gemma Marsden, Carole Johnston, J. Athene Lane, Marta Ebbing, Kaare Harald Bønaa, Ottar Nygård, Per Magne Ueland, Maria V. Grau, John A. Baron, Jenny L. Donovan, David E. Neal, Freddie C. Hamdy, A. David Smith, Richard M. Martin

Supplementary Table 2 from Circulating Folate, Vitamin B₁₂, Homocysteine, Vitamin B₁₂ Transport Proteins, and Risk of Prostate Cancer: a Case-Control Study, Systematic Review, and Meta-analysis

History

ARTICLE ABSTRACT

Background: Disturbed folate metabolism is associated with an increased risk of some cancers. Our objective was to determine whether blood levels of folate, vitamin B12, and related metabolites were associated with prostate cancer risk.Methods: Matched case-control study nested within the U.K. population–based Prostate testing for cancer and Treatment (ProtecT) study of prostate-specific antigen–detected prostate cancer in men ages 50 to 69 years. Plasma concentrations of folate, B12 (cobalamin), holo-haptocorrin, holo-transcobalamin total transcobalamin, and total homocysteine (tHcy) were measured in 1,461 cases and 1,507 controls. ProtecT study estimates for associations of folate, B12, and tHcy with prostate cancer risk were included in a meta-analysis, based on a systematic review.Results: In the ProtecT study, increased B12 and holo-haptocorrin concentrations showed positive associations with prostate cancer risk [highest versus lowest quartile of B12 odds ratio (OR) = 1.17 (95% confidence interval, 0.95-1.43); Ptrend = 0.06; highest versus lowest quartile of holo-haptocorrin OR = 1.27 (1.04-1.56); Ptrend = 0.01]; folate, holo-transcobalamin, and tHcy were not associated with prostate cancer risk. In the meta-analysis, circulating B12 levels were associated with an increased prostate cancer risk [pooled OR = 1.10 (1.01-1.19) per 100 pmol/L increase in B12; P = 0.002]; the pooled OR for the association of folate with prostate cancer was positive [OR = 1.11 (0.96-1.28) per 10 nmol/L; P = 0.2) and conventionally statistically significant if ProtecT (the only case-control study) was excluded [OR = 1.18 (1.00-1.40) per 10 nmol/L; P = 0.02].Conclusion: Vitamin B12 and (in cohort studies) folate were associated with increased prostate cancer risk.Impact: Given current controversies over mandatory fortification, further research is needed to determine whether these are causal associations. Cancer Epidemiol Biomarkers Prev; 19(6); 1632–42. ©2010 AACR.